<DOC>
	<DOC>NCT02320630</DOC>
	<brief_summary>This trial aims to compare the cost effective and effect of preventing recurrence by different treatment of TFP and HCQ combined SSZ for remittent RA.</brief_summary>
	<brief_title>Combination Therapy Prevents the Relapse of RA</brief_title>
	<detailed_description>patients were divided into 3groups: Group A:TFP+MTX (week0-week60) Group B:TFP+MTX+HCQ+SSZ(week0-week12) and then MTX+HCQ+SSZ(week13-week60) Group C:TFP+MTX (week0-week12) and then MTX (week13-week60)</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Disease Attributes</mesh_term>
	<criteria>Fulfill 2010 EULAR/ACR RA dignose criteria Age1870 years old Have been teated regularly for 3 months Disease duration &gt; 6months DAS28&gt;3.2 Received surgical operation in 8 weeks Received other biological agent (eg. rituximab, antiTNF agents, antiIL6 agents)in 6 months; Injection of steroid in 4 weeks Coexisting with other CTD except for SS With severe and not controled cardiac vescular disease, neurological disease, pulmonary disease (including COPD and ILD), renal disease, liver disease, endocrine disease and Gastric Intestinal Disease With not controled diseases including asthma, IBD and psoriasis needing oral or injection of steroid Active infection with T&gt;38℃. Patients need admitted into hospital or biotics injection in 4 weeks or need oral biotics in 2 weeks Malignant history. Serum creatinine &gt;130 µmol/L AST/ALT higher than 2 times upper level platelet count&lt;100 x 109/L，or white blood count&lt;3 x 109/L Interstitail lung disease: Chest X Ray Hands X Ray ACR radiology staging shows IV stage RA Pregnancy or planing to pregnant in 2 years or suckling period women.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>